News NHS trial puts AI for breast cancer screening under scrutiny Nearly 700,000 women will be recruited into an NHS trial of AI tools for breast cancer screening, in the hope of relieving pressure on radiologists.
News Sickle cell gene therapy Casgevy finally cleared for NHS use Vertex's gene-editing therapy for sickle cell disease, Casgevy, has been given the nod for use by the NHS in England after an earlier rejection.
News Dust mite allergy sufferers set for a new NHS treatment ALK-Abello's Acarizax for dust mite allergy should soon be available through the NHS in England, Wales and Northern Ireland, but not in Scotland.
News UK kicks off £150m tender process for healthcare AI The UK government has launched a £150 million procurement drive for artificial intelligence tools that can be used by the NHS.
News Santhera preps UK Duchenne drug launch after NICE says yes Santhera will launch its new drug for Duchenne muscular dystrophy in the UK within the next few weeks after getting the green light for NHS coverage.
Market Access Why the NHS needs to maximise the impact of biosimilars Ensuring the long-term sustainability of the NHS increasingly appears to be an unfathomable prospect.
R&D Ben Sidders on integrating causality in AI for R&D success Ben Sidders, chief scientific officer at Biorelate, discusses leveraging advanced data science methods to transform the focus and impact of R&D.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face